These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11018193)

  • 1. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
    Nakamura Y; Yamaoka O; Uchida K; Morigami N; Sugimoto Y; Fujita T; Inoue T; Fuchi T; Hachisuka M; Ueshima H; Shimakawa H; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):475-83. PubMed ID: 8924063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty.
    Onaka H; Hirota Y; Kita Y; Tsuji R; Ishii K; Ishimura T; Kawamura K
    Jpn Circ J; 1994 Feb; 58(2):100-6. PubMed ID: 8196151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
    Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
    Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preventive effect of pravastatin on restenosis following coronary angioplasty: prospective randomized trial].
    Iwasaki K; Kusachi S; Hina K; Yamasaki S; Nishiyama O; Takaishi A; Kita T; Taniguchi G
    J Cardiol; 1995 Jan; 25(1):15-21. PubMed ID: 7877098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty.
    Manfrini O; Pizzi C; Morgagni G; Fontana F; Bugiardini R
    Am J Cardiol; 2004 Jun; 93(11):1391-3, A6. PubMed ID: 15165921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
    Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pravastatin (mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate.
    Yui Y; Kawai C; Hosoda S
    Ann N Y Acad Sci; 1995 Jan; 748():208-16. PubMed ID: 7695166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial.
    Mulder HJ; Schalij MJ; Kauer B; Visser RF; van Dijkman PR; Jukema JW; Zwinderman AH; Bruschke AV
    Heart; 2001 Nov; 86(5):533-9. PubMed ID: 11602546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.